Lansoprazole sulfide
Based on 1 Customer Validation
Lansoprazole sulfide is an active metabolite of Lansoprazole by cytochrome P450, possesses anti-cancer activity. Lansoprazole sulfide is an anti-tuberculous agent, with an IC50 of 0.59 µM for M. tb.
For research use only. We do not sell to patients.
- Purity: 99.91%
- CAS No.: 103577-40-8
- Formula: C16H14F3N3OS
- Molecular Weight:353.37
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Chemical Information
-
CAS No. 103577-40-8
-
Appearance Solid
-
Molecular Weight 353.37
-
Formula C16H14F3N3OS
-
Color White to off-white
-
SMILES
FC(F)(F)COC1=C(C)C(CSC2=NC3=CC=CC=C3N2)=NC=C1
-
Synonyms
AG-1777
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (282.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Jenny Beebe, et al. Therapeutic Activity of the Lansoprazole Metabolite 5-Hydroxy Lansoprazole Sulfide in Triple-Negative Breast Cancer by Inhibiting the Enoyl Reductase of Fatty Acid Synthase. J Med Chem. 2022 Oct 27;65(20):13681-13691. [Content Brief]
[2]. Sipho Mdanda, et al. Lansoprazole-sulfide, pharmacokinetics of this promising anti-tuberculous agent. Biomed Chromatogr. 2017 Dec;31(12). [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8299 mL | 14.1495 mL | 28.2990 mL | 70.7474 mL |
| 5 mM | 0.5660 mL | 2.8299 mL | 5.6598 mL | 14.1495 mL | |
| 10 mM | 0.2830 mL | 1.4149 mL | 2.8299 mL | 7.0747 mL | |
| 15 mM | 0.1887 mL | 0.9433 mL | 1.8866 mL | 4.7165 mL | |
| 20 mM | 0.1415 mL | 0.7075 mL | 1.4149 mL | 3.5374 mL | |
| 25 mM | 0.1132 mL | 0.5660 mL | 1.1320 mL | 2.8299 mL | |
| 30 mM | 0.0943 mL | 0.4716 mL | 0.9433 mL | 2.3582 mL | |
| 40 mM | 0.0707 mL | 0.3537 mL | 0.7075 mL | 1.7687 mL | |
| 50 mM | 0.0566 mL | 0.2830 mL | 0.5660 mL | 1.4149 mL | |
| 60 mM | 0.0472 mL | 0.2358 mL | 0.4716 mL | 1.1791 mL | |
| 80 mM | 0.0354 mL | 0.1769 mL | 0.3537 mL | 0.8843 mL | |
| 100 mM | 0.0283 mL | 0.1415 mL | 0.2830 mL | 0.7075 mL |